Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + etoposide + fluorouracil + leucovorin + mitomycin
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FUMEP is a combination chemotherapy regimen consisting of cisplatin, etoposide (VP-16), fluorouracil (5-FU), leucovorin (citrovorum factor), and mitomycin. It has been investigated and utilized primarily as a salvage or consolidation therapy for advanced, recurrent, or aggressive malignancies, including inflammatory breast cancer (IBC) and multiple myeloma. The regimen combines multiple cytotoxic mechanisms to overcome drug resistance: cisplatin and mitomycin act as DNA alkylating and crosslinking agents; etoposide inhibits DNA topoisomerase II; and fluorouracil, whose activity is biochemically enhanced by leucovorin, acts as an antimetabolite inhibiting thymidylate synthase. This multi-agent approach aims to maximize tumor cell death but is associated with significant hematological and systemic toxicities.
- Other names
- FUMEPFUMEP protocolFUMEP regimen
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + etoposide + fluorouracil + leucovorin + mitomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + etoposide + fluorouracil + leucovorin + mitomycin.